A Case Report on Zoledronic Acid as Palliative Treatment in Carcinoma of Lung with Bone Metastasis

[1] Nakahara Y, Hosomi Y, Shibuya M, Mitsufuji H, Katagiri M, Naoki K, etal. Multicenter study of Zolendronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017. MolClinOncol. 2019 Oct 1;11(4):349–53. NakaharaY HosomiY ShibuyaM MitsufujiH KatagiriM NaokiK Multicenter study of Zolendronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017 MolClinOncol 2019 Oct 1 11 4 349 53 Search in Google Scholar

[2] Landi L, D’Incà F, Gelibter A, Chiari R, Grossi F, Delmonte A, etal. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer. 2019 Dec;7(1):1–9. LandiL D’IncàF GelibterA ChiariR GrossiF DelmonteA Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer J Immunother Cancer 2019 Dec 7 1 1 9 Search in Google Scholar

[3] Clézardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, et al. Bone metastasis: Mechanisms, therapies, and biomarkers. Physiol Rev. 2021 Jul 1;101(3):797–855. ClézardinP ColemanR PuppoM OttewellP BonnelyeE PaychaF Bone metastasis: Mechanisms, therapies, and biomarkers Physiol Rev 2021 Jul 1 101 3 797 855 Search in Google Scholar

[4] Tam AH, Schepers AJ, Qin A, Nachar VR. Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases. Ann Pharmacother. 2021 Jun;55(6):697–704. TamAH SchepersAJ QinA NacharVR Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases Ann Pharmacother 2021 Jun 55 6 697 704 Search in Google Scholar

[5] Zhang G, Cheng R, Zhang Z, Jiang T, Ren S, Ma Z, et.al. Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. Sci Rep. 2017 Feb 17;7(1):1–7. ZhangG ChengR ZhangZ JiangT RenS MaZ Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases Sci Rep 2017 Feb 17 7 1 1 7 Search in Google Scholar

[6] Belwal CK, Patel J. Solvent-free synthesis for imidazole-1-yl-acetic acid hydrochloride: an intermediate for Zolendronic acid. Asian J Green Chem. 2019;3(4):483–91. BelwalCK PatelJ Solvent-free synthesis for imidazole-1-yl-acetic acid hydrochloride: an intermediate for Zolendronic acid Asian J Green Chem 2019 3 4 483 91 Search in Google Scholar

[7] Zoledronic acid. In: In Depth Answers [Internet database]. Greenwood Village (CO): IBM Corporation; 2022 [cited 2022 Aug 21]. Available from: www.micromedexsolutions.com Zoledronic acid In: In Depth Answers [Internet database] Greenwood Village (CO) IBM Corporation 2022 [cited 2022 Aug 21]. Available from: www.micromedexsolutions.com Search in Google Scholar

[8] Noronha V, Pinninti R, Patil VM, Joshi A, Prabhash K. Lung cancer in the Indian subcontinent. South Asian J Cancer. 2016;5(03):95–103. NoronhaV PinnintiR PatilVM JoshiA PrabhashK Lung cancer in the Indian subcontinent South Asian J Cancer 2016 5 03 95 103 Search in Google Scholar

[9] Malik PS, Raina V. Lung cancer: prevalent trends & emerging concepts. Indian J Med Res. 2015;141(1):5. MalikPS RainaV Lung cancer: prevalent trends & emerging concepts Indian J Med Res 2015 141 1 5 Search in Google Scholar

[10] Zhou Y, Yu QF, Peng AF, Tong WL, Liu JM, Liu ZL. The risk factors of bone metastases in patients with lung cancer. Sci Rep. 2017;7(1):1–6. ZhouY YuQF PengAF TongWL LiuJM LiuZL The risk factors of bone metastases in patients with lung cancer Sci Rep 2017 7 1 1 6 Search in Google Scholar

[11] Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D’alessandro A, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br. J. Cancer. 2003;88(12):1971–8. TassoneP TagliaferriP ViscomiC PalmieriC CaragliaM D’alessandroA Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro Br. J. Cancer. 2003 88 12 1971 8 Search in Google Scholar

[12] Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases. Clin. Breast Cancer. 2012;12(4):247–58. XieJ DienerM SorgR WuEQ NamjoshiM Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases Clin. Breast Cancer. 2012 12 4 247 58 Search in Google Scholar